| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Colorectal Adenocarcinoma | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Adenocarcinoma | |||||
| 3 | More general conditions related to this trial | ||||
| Carcinoma | |||||
| Neoplasms | |||||
| Neoplasms by Histologic Type | |||||
| Neoplasms, Glandular and Epithelial | |||||
| 4 | Interventions listed in this trial | ||||
| bevacizumab + everolimus | |||||
| 5 | Additional drug interventions recognized in this trial | ||||
| Bevacizumab | |||||
| Everolimus | |||||
| 6 | More general drug interventions related to this trial | ||||
| Angiogenesis Inhibitors | |||||
| Angiogenesis Modulating Agents | |||||
| Antineoplastic Agents | |||||
| Growth Inhibitors | |||||
| Growth Substances | |||||
| Immunologic Factors | |||||
| Immunosuppressive Agents | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| Therapeutic Uses | |||||
| 7 | Sponsors listed in this trial | ||||
| Duke University | |||||
| Novartis | |||||
| Genentech | |||||
|
